Tom has 37 years experience in pharmaceutical, biologic, device and aesthetic-related sales, marketing and general management roles.
Tom is currently President and CEO of Recros Medica . Since 2011, he had been Chairman and CEO of Andrew Technologies LLC, an aesthetic surgical device company. Tom was also on the Board of Directors of Bonti, from 2016 to its acquisition by Allergan in 2018.
From 2010 to 2011, he was president of the topical aesthetic division at Syneron Medical Ltd, a global medical aesthetic device company. His medical aesthetic experience commenced with Allergan (2000 – 2008), where he led the launch of BOTOX ® Cosmetic and the commercial development of Latisse ®. He has extensive experience in cardiovascular, neurologic, anti-infectives, women’s healthcare and metabolic disorders, among other disease states. Prior to beginning his healthcare career, Tom was an officer in the US Air Force. He has a BS in biology from The Citadel and an MBA in marketing from Mercer University.
Our team at Dale Biotech recognizes the need for the best scientific minds to come together to tackle the current health crisis related to COVID-19.
We are also committed to using our expertise with Rhamnolipids to develop an oral formulation which is not only efficacious but also cost effective. Our experience with Rhamnolipids and our early research with niclosamide, has led us to a unique formulation that has the potential to not only treat early cases of COVID-19 but also could be used for prophylaxis against COVID-19 and other future viral threats.
Please join us , as an investor or as follower, and support our efforts to combat this worldwide pandemic.